Evidence map›Paper›PMID 35490384›Full record

ArticleJournal of the European Academy of Dermatology and Venereology : JEADV2022

Skin lesions in neurofibromatosis type 2: diagnostic and prognostic significance of cutaneous (plexiform) schwannomas.

A Plana-Pla, B García, M Munera-Campos, N Catasus, E Serra Arenas, I Blanco, E Castellanos Perez, I Bielsa, NF2 Multidisciplinary Clinics HUGTiP-ICO-IGTP

Open access · hybridAbstract read
In one paragraph

Article in Journal of the European Academy of Dermatology and Venereology : JEADV, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Molecular therapy. Nucleic acids · 2026
    Article
  2. Cancer predisposition syndromes: an imaging review.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

A Plana-PlaDermatology Department, Hospital Universitari Germans Trias I Pujol (HUGTiP), Badalona, Spain.ORCID https://orcid.org/0000-0003-2241-5664
B GarcíaClinical Genetics and Genetic Counseling Unit, Clinical Genetics Service, Northern Metropolitan Clinical Laboratory, Germans Trias i Pujol University Hospital (HUGTiP), Barcelona, Spain.
M Munera-CamposDermatology Department, Hospital Universitari Germans Trias I Pujol (HUGTiP), Badalona, Spain.ORCID https://orcid.org/0000-0002-2227-2993
N CatasusClinical Genomics Research Unit, Germans Trias i Pujol Research Institute (IGTP-PMPPC), Barcelona, Spain.
E Serra ArenasHereditary Cancer Group, Germans Trias i Pujol Research Institute (IGTP-PMPPC), Barcelona, Spain.
I BlancoClinical Genetics and Genetic Counseling Unit, Clinical Genetics Service, Northern Metropolitan Clinical Laboratory, Germans Trias i Pujol University Hospital (HUGTiP), Barcelona, Spain.
E Castellanos PerezClinical Genomics Research Unit, Germans Trias i Pujol Research Institute (IGTP-PMPPC), Barcelona, Spain.
I BielsaDermatology Department, Hospital Universitari Germans Trias I Pujol (HUGTiP), Badalona, Spain.
NF2 Multidisciplinary Clinics HUGTiP-ICO-IGTP
Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol · ESUniversitat Autònoma de Barcelona · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeurofibromatosis type 2 (NF2) is a genetic disease characterized by the appearance of multiple tumours in the nervous system. Cutaneous lesions are common and may provide useful diagnostic and prognostic information, but they have not been widely studied.

objectivesTo characterize cutaneous lesions in a Spanish cohort of patients with NF2 and investigate associations with clinical and genetic severity.

methodsWe studied the clinical and histologic characteristics of cutaneous lesions in 49 patients with NF2 and analysed correlations with phenotype- and genotype-based severity scores. We collected information on the presence/absence of cutaneous lesions, location, age at onset, type of lesion, and histologic features. We also studied level of systemic involvement and genetic mutations involved.

resultsForty-nine patients (31 women [63.3%] and 18 men [36.7%]) were analysed, and 33 (67.3%) had cutaneous lesions presumed to be schwannomas. According to their clinical form, they were distributed as follows: 24 patients (48%) had deep tumours, 21 (42%) had plaque-like lesions, and 3 (6%) had superficial tumours. Histologic examination from 27 lesions analysed out 23 patients showed classic schwannoma or hybrid schwannoma-neurofibroma features in the 8 deep tumours biopsied and plexiform schwannoma features in the 17 plaque-like lesions and the 2 superficial tumours analysed. Early onset (first 2 decades of life) was reported by all patients with plaques and superficial tumours. In our cohort, 100% of the patients with plaque-like lesions and superficial tumours with microscopic features of plexiform schwannoma were in the 2 groups with the most severe clinical phenotypes, and 82.6% of them were in the 3 most severe genotype-based classes. CONCLUSIONS AND RELEVANCE: Cutaneous lesions, specially plexiform schwannomas, are common in NF2, and they usually appear at an early age providing useful diagnostic and prognostic information. These tumours are part of the spectrum of cutaneous manifestations in this disease. Although its diagnostic and prognostic value has been pointed out, there are few studies focussed on their analysis.

Indexed as

NeurilemmomaNeurofibromatosis 1Neurofibromatosis 2Skin DiseasesSkin NeoplasmsFemaleHumansPrognosis

Identifiers

PMID35490384
PMCPMC9543204
OpenAlexW4225253014

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.